|
시장보고서
상품코드
2102302
야간빈뇨 시장 규모, 점유율, 성장 분석 : 약물 계열별, 질환 병인별, 환자 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Nocturia Market Size, Share, and Growth Analysis, By Drug Class, By Disease Etiology, By Patient Type, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 야간빈뇨 시장 규모는 2024년에 38억 5,000만 달러로 평가되었으며, 2025년 41억 8,000만 달러에서 2033년까지 80억 7,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 8.57%로 성장할 것으로 전망됩니다.
의약품, 진단약, 디지털 헬스 솔루션을 포함하는 전 세계 야간빈뇨 시장은 65세 이상 성인의 상당 부분에 영향을 미치는 야간빈뇨를 해결하기 위한 것입니다. 이 증상은 수면 장애, 낙상 위험 증가, 심혈관질환, 삶의 질 저하와 관련이 있어 심각한 문제로 대두되고 있습니다. 이 시장은 유럽, 북미, 아시아태평양의 고령화를 배경으로, 항콜린제에 대한 의존에서 β-3 작용제와 같은 보다 표적화된 치료법으로 전환되어 왔습니다. 또한, 디지털 모니터링 플랫폼은 방광 활동 데이터를 활용해 맞춤형 치료 경로를 구축함으로써 치료 접근 방식을 혁신하고 있습니다. 웨어러블 수분 센서 및 AI 분석과 같은 혁신을 통해 실시간 조정이 가능해져 치료 순응도가 향상됩니다. 그 결과, 통합형 치료 솔루션을 통해 시장이 확대되고 투자가 유입되고 있습니다.
세계 야간빈뇨 시장의 성장요인
세계 야간빈뇨 시장은 특히 고령자에게서 두드러지게 나타나는 방광 용량 감소나 호르몬 조절의 변동 등, 노화에 따른 생리적 변화의 영향을 크게 받고 있습니다. 세계 인구의 고령화에 따라 65세 이상 고령자가 증가함에 따라 야간빈뇨의 유병률도 현저히 상승하고 있습니다. 이러한 인구통계학적 동향으로 인해 진단 평가, 치료 옵션, 지속적인 관리 전략 등 다양한 서비스에 대한 수요가 높아지고 있습니다. 그 결과, 이러한 환자 수요의 급증은 의약품, 의료기기, 지원 치료 등 여러 분야의 성장을 촉진하고 있으며, 이를 통해 야간빈뇨 솔루션 시장 전체의 확장을 견인하고 있습니다.
세계 야간빈뇨 시장의 제약요인
세계 야간빈뇨 시장은 치료법에 대한 보험 급여 정책이 불명확하다는 점으로 인해 큰 제약을 받고 있습니다. 일부 지역에서는 이러한 정책으로 인해 치료가 ‘필수’가 아닌 ‘선택적’으로 분류되어, 임상의들이 더 새롭고 고가의 치료법을 처방하는 것을 주저하게 만드는 원인이 되고 있습니다. 이러한 상황은 높은 본인 부담금으로 인해 환자들이 진료를 미루게 되는 결과로 이어지고 있습니다. 그 결과, 첨단 의약품 및 의료기기 솔루션의 보급이 저해되어 시장 전체의 성장을 방해하고 있습니다. 또한, 보험 적용 범위의 일관성 부족은 연구 개발 투자에 지속적인 장벽으로 작용하고 있습니다. 이는 전 세계적으로 지불 주체의 지원이 예측하기 어려운 시장에서 제조사들이 상업적 수익이 제한될 것을 우려하기 때문입니다.
세계 야간빈뇨 시장의 동향
세계 야간빈뇨 시장에서는 원격의료 도입에 힘입어 큰 변화가 나타나고 있으며, 환자가 전문적인 의료 서비스를 이용하는 방식이 근본적으로 변화하고 있습니다. 원격 진료 플랫폼이 보급되면서 환자들은 거주지에 관계없이 배뇨 증상에 대해 적시에 평가를 받을 수 있게 되었습니다. 이러한 진화로 인해 환자 참여도가 향상되고, 대기 시간이 최소화되며, 디지털 일지를 통한 지속적인 모니터링이 용이해집니다. 그 결과, 제약 회사와 의료기기 제조업체들은 원격의료 제공업체와 제휴하여 교육 자료와 치료 프로토콜을 온라인 진료에 통합하고 있습니다. 이러한 움직임은 야간빈뇨 관리를 효율화할 뿐만 아니라, 환자의 장기적인 건강 결과 개선도 목표로 하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 야간빈뇨 시장 규모 : 약물 계열별
세계의 야간빈뇨 시장 규모 : 질환 병인별
세계의 야간빈뇨 시장 규모 : 환자 유형별
세계의 야간빈뇨 시장 규모 : 투여 경로별
세계의 야간빈뇨 시장 규모 : 유통 채널별
세계의 야간빈뇨 시장 규모 : 최종사용자별
세계의 야간빈뇨 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.04Global Nocturia Market size was valued at USD 3.85 Billion in 2024 and is poised to grow from USD 4.18 Billion in 2025 to USD 8.07 Billion by 2033, growing at a CAGR of 8.57% during the forecast period (2026-2033).
The global nocturia market, which includes pharmaceuticals, diagnostics, and digital health solutions, addresses nighttime urination affecting a significant portion of adults over 65. This condition is critical due to its association with sleep disruption and increased risks of falls, cardiovascular issues, and diminished quality of life. The market has evolved from a reliance on anticholinergic agents to more targeted therapies like beta-3 agonists, driven by an aging population in regions such as Europe, North America, and Asia-Pacific. Additionally, digital monitoring platforms are transforming treatment approaches by utilizing bladder activity data to create personalized care pathways. Innovations, such as wearable moisture sensors and AI analytics, enable real-time adjustments and foster adherence, ultimately expanding the market and attracting investments through bundled treatment solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nocturia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Nocturia Market Segments Analysis
Global nocturia market is segmented by drug class, disease etiology, patient type, route of administration, distribution channel, end user and region. Based on drug class, the market is segmented into Antidiuretic Agents, Antimuscarinic Agents, Beta-3 Adrenergic Agonists, Alpha-Blockers, 5-Alpha Reductase Inhibitors, Combination Therapies and Others. Based on disease etiology, the market is segmented into Nocturnal Polyuria, Reduced Bladder Capacity and Mixed Nocturia. Based on patient type, the market is segmented into Adult, Geriatric and Pediatric. Based on route of administration, the market is segmented into Oral, Injectable and Intranasal. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Home Care Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Nocturia Market
The global nocturia market is significantly influenced by age-related physiological changes, including reduced bladder capacity and variations in hormone regulation, which are particularly noticeable in older adults. As the global population ages, with an increasing number of individuals aged sixty-five and older, there is a marked rise in the prevalence of nocturia. This demographic trend stimulates a growing demand for various services, including diagnostic assessments, treatment options, and ongoing management strategies. Consequently, this surge in patient needs is fostering growth across multiple sectors, including pharmaceuticals, medical devices, and supportive care, thereby driving the overall market expansion for nocturia solutions.
Restraints in the Global Nocturia Market
The global nocturia market faces significant restraints due to unclear reimbursement policies for treatment options. In several areas, these policies classify interventions as elective instead of essential, which creates hesitance among clinicians to prescribe newer, more expensive therapies. This situation also leads patients to postpone seeking care because of high out-of-pocket costs. As a result, the uptake of advanced pharmaceutical and device solutions is stymied, hindering the overall market growth. Additionally, the inconsistent coverage remains a barrier to investments in research and development, as manufacturers are concerned about limited commercial returns in markets characterized by unpredictable payer support worldwide.
Market Trends of the Global Nocturia Market
The Global Nocturia market is witnessing a significant trend driven by the integration of telemedicine, fundamentally transforming patient access to specialized care. Remote consultation platforms are becoming commonplace, allowing patients to receive timely evaluations of urinary symptoms regardless of their location. This evolution enhances patient engagement, minimizes wait times, and facilitates ongoing monitoring via digital diaries. As a result, pharmaceutical and device companies are forming partnerships with telehealth providers to weave educational resources and treatment protocols into virtual consultations. This development not only streamlines the management of nocturia but also aims to boost long-term health outcomes for patients.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Nocturia Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Antidiuretic Agents
- Antimuscarinic Agents
- Beta-3 Adrenergic Agonists
- Alpha-Blockers
- 5-Alpha Reductase Inhibitors
- Combination Therapies
- Others
Global Nocturia Market Size by Disease Etiology & CAGR (2026-2033)
- Market Overview
- Nocturnal Polyuria
- Reduced Bladder Capacity
- Mixed Nocturia
Global Nocturia Market Size by Patient Type & CAGR (2026-2033)
- Market Overview
- Adult
- Geriatric
- Pediatric
Global Nocturia Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
- Intranasal
Global Nocturia Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Nocturia Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Home Care Settings
Global Nocturia Market Size & CAGR (2026-2033)
- North America (Drug Class, Disease Etiology, Patient Type, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Drug Class, Disease Etiology, Patient Type, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Disease Etiology, Patient Type, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Disease Etiology, Patient Type, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Disease Etiology, Patient Type, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Ferring Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Avadel Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
